Baidu
map

Circ Heart Fail:心衰?多喝点甜菜根汁吧,有好处

2015-09-19 MedSci MedSci原创

心衰?多喝点甜菜根汁吧,有好处据发表于 Circulation: Heart Failure的一项研究表明,高硝酸盐(甜菜根汁中可大量发现)饮食可改善心衰患者的肌肉功能。硝酸盐是甜菜汁,菠菜及其他绿叶蔬菜(如芝麻菜和芹菜)的活性成分。研究人员曾发现,摄入高水平的硝酸盐可改善体育精英的肌肉性能。此次研究旨在探究甜菜汁是否有益于心衰患者的健康。研究仅纳入了9名患者,均接受甜菜汁治疗。采用双盲、自身对照

据发表于 Circulation: Heart Failure的一项研究表明,高硝酸盐(甜菜根汁中可大量发现)饮食可改善心衰患者的肌肉功能。

硝酸盐是甜菜汁,菠菜及其他绿叶蔬菜(如芝麻菜和芹菜)的活性成分。研究人员曾发现,摄入高水平的硝酸盐可改善体育精英的肌肉性能。此次研究旨在探究甜菜汁是否有益于心衰患者的健康。

研究仅纳入了9名患者,均接受甜菜汁治疗。采用双盲、自身对照法;一些患者的甜菜汁中去除了硝酸盐,作为安慰剂对照组。

结果发现,饮用含硝酸盐的甜菜汁后2小时,患者伸膝时其肌肉力量增加了13%,速度最快时,肌肉增加的力量也最大。

通过对比患者锻炼中肌肉力量的改善情况,研究人员评估了甜菜汁所带来益处的大小。

Andrew R. Coggan教授对比了甜菜汁对吃菠菜的大力水手的作用,发现甜菜汁对肌肉性能的改善程度相当于心衰患者做了3个月的阻力训练。

基于越来越多的关于硝酸盐对健康人及运动员作用的研究以及目前关于心衰患者的研究,研究人员欲探究硝酸盐对老年人的作用。

老化的其中一个问题就是肌肉变弱、速度变慢、力量变小。超过一定年龄后,肌肉功能每年都会减小1%。如果正如本研究所做的那样提高肌肉的力量,那么便可以为老年人带来明显地益处。

原始出处:

Coggan AR, Leibowitz JL, Spearie CA, Kadkhodayan A, Thomas DP, Ramamurthy S, Mahmood K, Park S, Waller S, Farmer M, Peterson LR.Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial. Circ Heart Fail. 2015 Sep;8(5):914-20.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1798328, encodeId=f2a51e98328ee, content=<a href='/topic/show?id=73d56885904' target=_blank style='color:#2F92EE;'>#甜菜根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68859, encryptionId=73d56885904, topicName=甜菜根)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Wed Jul 27 05:33:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356009, encodeId=e85913560094d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562319, encodeId=47d61562319d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37063, encodeId=57143e0639c, content=人们真是会发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:01:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2016-07-27 Boyinsh
  2. [GetPortalCommentsPageByObjectIdResponse(id=1798328, encodeId=f2a51e98328ee, content=<a href='/topic/show?id=73d56885904' target=_blank style='color:#2F92EE;'>#甜菜根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68859, encryptionId=73d56885904, topicName=甜菜根)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Wed Jul 27 05:33:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356009, encodeId=e85913560094d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562319, encodeId=47d61562319d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37063, encodeId=57143e0639c, content=人们真是会发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:01:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1798328, encodeId=f2a51e98328ee, content=<a href='/topic/show?id=73d56885904' target=_blank style='color:#2F92EE;'>#甜菜根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68859, encryptionId=73d56885904, topicName=甜菜根)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Wed Jul 27 05:33:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356009, encodeId=e85913560094d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562319, encodeId=47d61562319d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37063, encodeId=57143e0639c, content=人们真是会发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:01:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1798328, encodeId=f2a51e98328ee, content=<a href='/topic/show?id=73d56885904' target=_blank style='color:#2F92EE;'>#甜菜根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68859, encryptionId=73d56885904, topicName=甜菜根)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Wed Jul 27 05:33:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356009, encodeId=e85913560094d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562319, encodeId=47d61562319d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Sep 21 14:33:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37063, encodeId=57143e0639c, content=人们真是会发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:01:00 CST 2015, time=2015-09-21, status=1, ipAttribution=)]
    2015-09-21 nizongzan

    人们真是会发现

    0

相关资讯

JACC Cardiovasc Interv:新型ARTO系统治疗功能性二尖瓣返流安全有效

新型ARTO系统可改善二尖瓣返流(FMR),因此,本研究评估了新型ARTO系统对心力衰竭患者和功能性二尖瓣返流的治疗效果。 MAVERIC试验是一项前瞻性,非随机化的研究。关键入选标准为患者均为收缩性心衰、NYHA心功能II~IV级、功能性二尖瓣返流等级大于2级、左心室射血分数小于等于40%、左室舒张末期内径在50 mm~75 mm之间。主要安全性终点是30天主要不良事件,有效性终点为二尖瓣返流

CSC&OCC 2015:胡盛寿:心力衰竭外科治疗——挑战与突破

本文作者:北京阜外心血管病医院院长,中国工程院院士,美国心脏病学院会员胡盛寿。心力衰竭是一种全球性疾病,欧洲有超过1000万,美国超过580万,中国超过500万人患有心力衰竭。30-65岁人群发病率为1.5-2.0%,65岁以上人群发病率为6-10%。心力衰竭是全球吃唯一呈增长趋势的心脏疾病,是心血管病领域未来要面临的巨大挑战。2003年,对中国10省市20个城区和农村15518人口调查显示,心衰

一周研究进展荟萃:让你知识满满!

通宵工作 癌细胞 β受体阻滞剂 睡眠 阿片类药物 心衰 动脉硬化

Hepatology:非酒精性脂肪肝患者可能导致心衰风险

非酒精性脂肪肝(NAFLD)和心力衰竭(HF)导致高心血管死亡率。非酒精性脂肪肝(NAFLD)与亚临床心肌重构及功能障碍是否相关,目前尚未知晓。 研究人员对2713名CARDIA患者进行横断面多中心分析。所收纳的患者中有8.8%为女性,48%为黑人,NAFLD患病率为10%(n=271)。研究人员通过计算机断层扫描(CT)进行肝部脂肪量化,通过超声斑点追踪成像技术测定心肌

JACC:心衰患者心脏康复治疗,你知道多少?

肯塔基,路易斯维尔大学医学院,Golwala H等人研究了心衰患者中心脏康复训练的使用率,趋势。其结果发表在8月份 Journal of the American College of Cardiology期刊上。背景:目前指南推荐病情稳定的门诊心脏衰竭(HF)患者进行心脏康复训练(CR);然而,现实世界中,心衰患者与心脏康复治疗相关的治疗趋势及其影响因素并不完全已知。目的:这项研究旨在评估失代偿

JACC Heart Fail:急性失代偿性心衰(ADHF)患者β受体阻滞剂治疗不能停

以往的研究中,显示停用β受体阻滞剂会增加急性失代偿性心衰(ADHF)患者的死亡率和再入院风险,但并没有进行全面的分析。本研究评估并分析了β受体阻滞剂对急性失代偿性心衰(ADHF)患者的影响。 研究人员通过检索PubMed, EMBASE和COCHRANE电子数据库收纳了来自2000年到2015年1月期间发表的相关研究,这些研究主要比较继续和中断β受体阻滞剂治疗的急性失代偿性心衰研究。 共5项观

Baidu
map
Baidu
map
Baidu
map